I swear everytime a scientific study is posted on here a bunch of know nothings who haven't been in a lab since high school think they have the answers.
They provided evidence to back their claims so if you can't provide evidence to the contrary just stop talking.
Y'all think they'll be handing people an eighth of shrooms
. Any medication will be at such a low dose there's no high whatsoever. Mushrooms aren't like other drugs. You can't trip on them often because you develop a tolerance. Even people who shroom heavy will tell you they take month long breaks or longer. Some people may only wait two weeks but the effects are very light when consumed that often.
There's been plenty of studies on psylocin for mental health issues and it's way more promising that the current drugs big pharma is pushing.
pubmed.ncbi.nlm.nih.gov
They provided evidence to back their claims so if you can't provide evidence to the contrary just stop talking.
Y'all think they'll be handing people an eighth of shrooms
. Any medication will be at such a low dose there's no high whatsoever. Mushrooms aren't like other drugs. You can't trip on them often because you develop a tolerance. Even people who shroom heavy will tell you they take month long breaks or longer. Some people may only wait two weeks but the effects are very light when consumed that often.There's been plenty of studies on psylocin for mental health issues and it's way more promising that the current drugs big pharma is pushing.
The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation underlies a significant subset of psychiatric conditions, particularly major depressive and anxiety disorders. Anti-inflammatory interventions have demonstrated benefit in these conditions. Psilocin, the active ingredient of mushrooms in the Psilocybe genus, is both a potent serotonin agonist and anti-inflammatory agent, increases neuroplasticity, and decreases overactivity in the default mode network. Studies using hallucinogenic doses of psilocin under the supervision of a therapist/guide have consistently demonstrated benefits to individuals with depression and end-of-life anxiety. Microdosing psilocybin in sub-hallucinogenic doses has also demonstrated benefit in mood disorders, and may offer a safe, less expensive, and more available alternative to full doses of psilocybin for mood disorders, as well as for other medical conditions in which inflammation is the principal pathophysiology.
Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity - PubMed
The incidence of mental health disorders is increasing worldwide. While there are multiple factors contributing to this problem, neuroinflammation underlies a significant subset of psychiatric conditions, particularly major depressive and anxiety disorders. Anti-inflammatory interventions have...